Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
Front Med (Lausanne) ; 11: 1328719, 2024.
Article in English | MEDLINE | ID: mdl-38799147

ABSTRACT

Background: To date, the correlation between CD4 on the monocytes (mCD4) expression and the prognosis of patients with septic shock remains unclear. The purpose of this study was to analyze the expression of mCD4 in these patients and further evaluate whether mCD4 expression correlates with either the recovery from multiple organ dysfunction syndrome (MODS) or mortality. Methods: The study participants were recruited from a tertiary general hospital in China (Affiliated Dongyang Hospital of Wenzhou Medical University). Sepsis and septic shock were diagnosed based on the diagnostic criteria of Sepsis-3. MODS was defined as a Sequential Organ Failure Assessment score of at least two organ systems ≥2. Persistent MODS was defined as the continual meeting of the MODS criteria when re-evaluated one week after admission (day 7). A logistic regression model was used to test whether mCD4 was an independent prognostic factor for mortality in patients with septic shock. A paired sample rank sum test was used to examine the correlation between mCD4 expression and MODS recovery. Result: The study recruited 79 patients with septic shock as the study group, 74 patients with sepsis as the disease control group, and 56 volunteers as healthy controls. In the first 24 h after admission (day 1), mCD4 expression was significantly reduced in patients with septic shock compared to healthy controls and patients with sepsis. Moreover, mCD4 expression was an independent prognostic factor for in-hospital and 28 day mortality in patients with septic shock. mCD4 expression did not show significant differences in patients with persistent MODS on day 7 compared to day 1. However, mCD4 expression was significantly higher in patients without persistent MODS on day 7 than on day 1. Conclusion: mCD4 expression is significantly reduced in patients with septic shock, which is an independent prognostic factor for mortality and closely related to recovery from MODS.

2.
Rev. Univ. Ind. Santander, Salud ; 52(4): 422-430, Octubre 21, 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1340841

ABSTRACT

Resumen Introducción: El COVID-19 es una enfermedad infecciosa ocasionada por el virus RNA SARS-CoV-2, con una alta tasa de contagio y con un curso clínico heterogéneo. Existe evidencia que en fase avanzada de COVID-19 hay un riesgo aumentado de coagulación intravascular diseminada. Por lo tanto, el manejo con heparinas debe ser considerado como una estrategia terapéutica. Objetivos: Nuestro objetivo principal es mostrar la literatura más relevante disponible, con referencia a la utilidad de la anticoagulación en el manejo de la hipercoagulabilidad en los pacientes con COVID-19 graves. Metodología: Se realizó una revisión narrativa a partir de la búsqueda avanzada con los términos DeSC: Infecciones por Coronavirus; SARS-CoV; Coagulación Sanguínea; Coagulación Intravascular Diseminada; Disfunción orgánica múltiple; Sepsis; Síndrome de respuesta inflamatoria sistémica; Lesión renal aguda. Se utilizaron los motores de búsqueda Clinical Key, Embase, PubMed y Ovid, obteniendo un total de 143 resultados, entre artículos originales, reportes de casos, series de casos y revisiones de la literatura, se seleccionaron un total de 56 artículos que fueron utilizados para la elaboración de la presente revisión de tema. Conclusiones: El manejo con heparinas debe ser considerado como una estrategia terapéutica. Continuamos con la necesidad de futuros estudios que indaguen interrogantes en el paciente COVID-19 hospitalizado, especialmente que definan, evaluando riesgo/beneficio, que se justifica o no con respecto a la anticoagulación plena en algunos pacientes específicos con COVID-19.


Abstract Introduction: COVID-19 is an infectious disease caused by the RNA SARS-CoV-2 virus, with a high rate of infection and a heterogeneous clinical course. There is evidence that in the advanced phase of COVID-19 there is an increased risk of disseminated intravascular coagulation. Therefore, heparin management should be considered as a therapeutic strategy. Objectives: Our main objective is to show the most relevant literature available, with reference to the usefulness of anticoagulation in the management of hypercoagulability in patients with COVID-19 and severe manifestations. Methodology: A narrative review was performed from the advanced search with the terms DeSC: Coronavirus Infections; SARS-CoV; Blood Coagulation; Disseminated intravascular coagulation; Multiple organic dysfunction; Sepsis; Systemic inflammatory response syndrome; Acute kidney injury. The Clinical Key, Embase, PubMed and Ovid search engines were used, obtaining a total of 143 results, among original articles, case reports, case series and literature reviews, a total of 56 articles were selected that were used to the preparation of this topic review. Conclusions: Heparin management should be considered as a therapeutic strategy. We continue with the need for future studies that investigate questions in the hospitalized COVID-19 patient, especially defining, evaluating risk / benefit, which is justified or not with respect to full anticoagulation in some specific patients with COVID-19.


Subject(s)
Humans , Blood Coagulation , Coronavirus Infections , COVID-19 , Anticoagulants , Systemic Inflammatory Response Syndrome , Sepsis , Severe acute respiratory syndrome-related coronavirus , Disseminated Intravascular Coagulation , Acute Kidney Injury , Organ Dysfunction Scores
SELECTION OF CITATIONS
SEARCH DETAIL
...